LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR plus ) metastatic breast cancer.

被引：13
|
作者：
Patnaik, Amita
Rosen, Lee S.
Tolaney, Sara M.
Tolcher, Anthony W.
Goldman, Jonathan Wade
Gandhi, Leena
Papadopoulos, Kyriakos P.
Beeram, Muralidhar
Rasco, Drew Warren
Myrand, Scott P.
Kulanthaivel, Palaniappan
Andrews, Joan M.
Frenzel, Martin
Cronier, Damien
Chan, Edward M.
Flaherty, Keith
Wen, Patrick Y.
Shapiro, Geoffrey
机构：
[1] South Texas Accelerated Res Therapeut START Ctr C, San Antonio, TX USA
[2] UCLA Santa Monica Hematol Oncol, Santa Monica, CA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
[6] Dana Farber Canc Ctr Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
534
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
    Patnaik, Amita
    Rosen, Lee S.
    Tolaney, Sara M.
    Tolcher, Anthony W.
    Goldman, Jonathan W.
    Gandhi, Leena
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Rasco, Drew W.
    Myrand, Scott P.
    Kulanthaivel, Palaniappan
    Li, Lily
    Frenzel, Martin
    Cronier, Damien M.
    Chan, Edward M.
    Flaherty, Keith T.
    Wen, Patrick Y.
    Shapiro, Geoffrey I.
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.
    Goldman, Jonathan Wade
    Gandhi, Leena
    Patnaik, Amita
    Rosen, Lee S.
    Hilton, John Frederick
    Papadopoulos, Kyriakos P.
    Tolaney, Sara M.
    Beeram, Muralidhar
    Rasco, Drew Warren
    Myrand, Scott P.
    Beckmann, Richard P.
    Kulanthaivel, Palaniappan
    Frenzel, Martin
    Cronier, Damien
    Chan, Edward M.
    Flaherty, Keith
    Wen, Patrick Y.
    Tolcher, Anthony W.
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer.
    Dempsey, Jack A.
    Chan, Edward M.
    Burke, Teresa F.
    Beckmann, Richard P.
    CANCER RESEARCH, 2013, 73 (08)
  • [4] A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.
    Shapiro, Geoffrey
    Rosen, Lee S.
    Tolcher, Anthony W.
    Goldman, Jonathan Wade
    Gandhi, Leena
    Papadopoulos, Kyriakos P.
    Tolaney, Sara M.
    Beeram, Muralidhar
    Rasco, Drew Warren
    Kulanthaivel, Palaniappan
    Li, Qian
    Hu, Tianle
    Cronier, Damien
    Chan, Edward M.
    Flaherty, Keith
    Wen, Patrick Y.
    Patnaik, Amita
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Morschhauser, Franck
    Bouabdallah, Kamal
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Wolf, Martin
    de Guibert, Sophie
    Zettl, Florian
    Hahka-Kemppinen, Marjo
    Wang, David Xiaohui
    Brueck, Patrick
    Caldwell, Charles
    Beckmann, Richard
    Gelbert, Lawrence
    Cronier, Damien
    Lin, Ji
    Li, Lily
    Chan, Edward M.
    Pfreundschuh, Michael
    Wilhem, Martin
    Hess, Georg
    BLOOD, 2014, 124 (21)
  • [6] The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
    Ku, Bo Mi
    Yi, Seong Yoon
    Koh, Jiae
    Bae, Yeon-Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    ONCOTARGET, 2016, 7 (12) : 14803 - 14813
  • [7] Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma
    Ahn, Myung-Ju
    Ku, Bo Mi
    Yi, Seong Yoon
    Koh, Jiae
    Bae, Yeon-Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Gut microbiome predicts response to CDK4/6 inhibitor and immune check point inhibitor combination in patients with hormone receptor positive metastatic breast cancer.
    Wong, Chi Wah
    Yost, Susan E.
    Lee, Jin Sun
    Highlander, Sarah K.
    Yuan, Yuan
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Breast cancer: CDK4/6 inhibitor plus fulvestrant prolongs survival
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02)
  • [10] Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
    Lawrence M. Gelbert
    Shufen Cai
    Xi Lin
    Concepcion Sanchez-Martinez
    Miriam del Prado
    Maria Jose Lallena
    Raquel Torres
    Rose T. Ajamie
    Graham N. Wishart
    Robert Steven Flack
    Blake Lee Neubauer
    Jamie Young
    Edward M. Chan
    Philip Iversen
    Damien Cronier
    Emiko Kreklau
    Alfonso de Dios
    Investigational New Drugs, 2014, 32 : 825 - 837
12345